# Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine

> **NCT05107115** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 161 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** rilzabrutinib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05107115
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-24
- **Primary completion:** 2023-07-19
- **Final completion:** 2024-04-23
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05107115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05107115, "Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT05107115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*